Business
Hardman Research: Major deal to supply Novartis
Hardman Research: Major deal to supply Novartis.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 4476K Oxford Biomedica PLC 07 July 2017 \n\nHardman Research: Major deal to supply Novartis\nMajor deal to supply Novartis CAR-T programmes - OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform. OXB has made two significant announcements during the past week which reduce risk and greatly improve sentiment towards the stock. First, refinancing of its existing loan with a new, more favourable debt facility from Oakland Capital. Secondly, a deal with Novartis to supply vector for use in the manufacture of certain CAR-T therapies.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/07.07.17-major-deal-to-supply-novartis-car-t-programmes.pdf\n\n\n\n\nTo contact us: \nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\n\n\nContacts:\nDr Martin Hall\[email protected] \nDr Dorothea Hill\[email protected]\nDr Gregoire Pave\[email protected]\nTelephone: +44 20 7194 7622\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterpa...